Torsade de pointes (TdP) is increasingly recognized as a complication of drug therapy. The most common cause of drug-induced QT prolongation is inhibition of the rapidly activating component of the delayed potassium current (I(Kr)). Moxifloxacin, a widely used fluoroquinolone, is a weak I(Kr) inhibitor and has been associated with QT prolongation. We report a case of marked QT prolongation (618 ms) and TdP associated with moxifloxacin use. Although it is difficult to predict which patients are at risk from TdP, careful assessment of the risk/benefit ratio is important before prescribing drugs known to cause QT prolongation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review.
Expert Opin Drug Saf
October 2018
a Department of Pharmacy , University of Peshawar, Peshawar , Khyber Pakhtunkhwa , Pakistan.
Introduction: Moxifloxacin is widely used for the treatment of a number of infectious diseases because of its favorable pharmacological profile and high clinical success rate. However, it is often criticized for its higher risk of QTc interval prolongation (QTIP) and torsades de pointes (TdP).
Areas Covered: A review of published literature on moxifloxacin-related QTIP and TdP.
Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys.
J Pharmacol Toxicol Methods
August 2011
Pharmacokinetics, Dynamics and Metabolism, Pfizer Global R&D, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK.
Introduction: Delayed ventricular repolarisation is manifested electrocardiographically in a prolongation of the QT interval. Such prolongation can lead to potentially fatal Torsades de Pointes. Moxifloxacin is a fluoroquinolone antibiotic which has been associated with QT prolongation and, as a result, is recommended by the regulatory authorities as a positive control in thorough QT studies performed to evaluate the potential of new chemical entities to induce QT prolongation in humans.
View Article and Find Full Text PDFHighly automated QT measurement techniques in 7 thorough QT studies implemented under ICH E14 guidelines.
Ann Noninvasive Electrocardiol
January 2011
Heart Research Follow-up Program, Cardiology Department, University of Rochester Medical Center, Rochester, NY 14642, USA.
Article Synopsis
- TQT studies assess how new drugs affect heart repolarization by measuring QTc prolongation, a potential indicator of dangerous heart rhythms.
- Developing an automated method for measuring QT intervals could streamline the process, as current methods are time-consuming and costly.
- The study validated a highly automatic-QT method, finding no significant differences in QTc prolongation results compared to the FDA-approved standards, suggesting the automation is as precise and effective.
Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug.
Am J Med Sci
August 2009
Department of Medical Education, Saint Joseph Mercy-Oakland, 44405 Woodward Avenue, Pontiac, MI 48341, USA.
Torsade de pointes (TdP) or "twisting of the points" represents polymorphic ventricular tachycardia in the setting of prolonged QT interval and is characterized by QRS complexes that change in morphology and amplitude. We report a rare case of TdP, associated with QT interval prolongation, caused by intravenous moxifloxacin given for pneumonia in a 71-year-old African American man. Electrocardiogram initially revealed QT interval prolongation that led to torsades de pointes.
View Article and Find Full Text PDFMoxifloxacin-induced torsades de pointes.
Cardiol J
October 2008
Unity Health System, Department of Medicine, University of Rochester Medical Center, Rochester, NY 14626, USA.
Torsade de pointes (TdP) is increasingly recognized as a complication of drug therapy. The most common cause of drug-induced QT prolongation is inhibition of the rapidly activating component of the delayed potassium current (I(Kr)). Moxifloxacin, a widely used fluoroquinolone, is a weak I(Kr) inhibitor and has been associated with QT prolongation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!